

Original Article: Basic Nanomedicine

# Endothelial permeability is controlled by spatially defined cytoskeletal mechanics: Atomic force microscopy force mapping of pulmonary endothelial monolayer

Anna A. Birukova, MD,<sup>a,1</sup> Fernando T. Arce, PhD,<sup>a,b,1</sup> Nurgul Moldobaeva, BS,<sup>a</sup>  
Steven M. Dudek, MD,<sup>a</sup> Joe G.N. Garcia, MD,<sup>a</sup>  
Ratnesh Lal, PhD,<sup>a,b</sup> Konstantin G. Birukov, MD, PhD<sup>a,\*</sup>

<sup>a</sup>*Division of Biomedical Sciences, Department of Medicine, Section of Pulmonary and Critical Care Medicine University of Chicago, Chicago, Illinois, USA*

<sup>b</sup>*Department of Medicine, Center for Nanomedicine, University of Chicago, Chicago, Illinois, USA*

## Abstract

Actomyosin contraction directly regulates endothelial cell (EC) permeability, but intracellular redistribution of cytoskeletal tension associated with EC permeability is poorly understood. We used atomic force microscopy (AFM), EC permeability assays, and fluorescence microscopy to link barrier regulation, cell remodeling, and cytoskeletal mechanical properties in EC treated with barrier-protective as well as barrier-disruptive agonists. Thrombin, vascular endothelial growth factor, and hydrogen peroxide increased EC permeability, disrupted cell junctions, and induced stress fiber formation. Oxidized 1-palmitoyl-2-arachidonoyl-*sn*-glycero-3-phosphocholine, hepatocyte growth factor, and iloprost tightened EC barriers, enhanced peripheral actin cytoskeleton and adherens junctions, and abolished thrombin-induced permeability and EC remodeling. AFM force mapping and imaging showed differential distribution of cell stiffness: barrier-disruptive agonists increased stiffness in the central region, and barrier-protective agents decreased stiffness in the center and increased it at the periphery. Attenuation of thrombin-induced permeability correlates well with stiffness changes from the cell center to periphery. These results directly link for the first time the patterns of cell stiffness with specific EC permeability responses.

© 2009 Elsevier Inc. All rights reserved.

## Key words:

Pulmonary endothelium; Permeability; Agonists; Actin cytoskeleton; Force mapping

Vascular leak resulting from endothelial barrier compromise is a cardinal feature of acute lung injury. A complete understanding of cellular mechanisms regulating endothelial permeability is important for development of novel thera-

peutic strategies for treatment of this devastating condition. The lung endothelium forms a semi-selective barrier between circulating blood and interstitial fluid, which is dynamically regulated by a counterbalance of barrier-protective and barrier-disruptive bioactive molecules present in the circulation.

Mechanisms governing vascular permeability are under intensive investigation. Models of agonist-induced endothelial cell (EC) permeability consider the regulation of EC permeability as the net balance of barrier-disrupting axial contractile forces produced by myosin light chain kinase (MLCK) and Rho-guanosine triphosphatase (Rho-GTPase)–driven actomyosin contraction, and barrier-promoting tethering/resistive forces produced by cell-cell, cell-matrix interactions, rigid cytoskeletal components (microtubules and

Received 2 January 2008; accepted 30 July 2008.

This work was supported by National Heart, Lung, and Blood Institutes grants HL076259, HL075349, and HL58064, the American Lung Association Career Investigator Grant (K.G.B.); National Scientist Developing Grant from the American Heart Association (A.A.B.), the American Lung Association Biomedical Research Grant (A.A.B.); and Department of Medicine Developmental Fund (R.L., F.T.A.).

\*Corresponding author. Division of Biomedical Sciences, Department of Medicine, Section of Pulmonary and Critical Medicine, University of Chicago, Chicago, IL 60637, USA.

E-mail address: [kbirukov@medicine.bsd.uchicago.edu](mailto:kbirukov@medicine.bsd.uchicago.edu) (K.G. Birukov).

<sup>1</sup> These authors contributed equally in this study.

1549-9634/\$ – see front matter © 2009 Elsevier Inc. All rights reserved.

doi:10.1016/j.nano.2008.07.002

intermediate filaments), and peripheral F-actin rim.<sup>1–5</sup> Actomyosin contraction and its distribution in nonmuscle cells have been monitored using immunofluorescent and biochemical labeling of actin remodeling, for example by monitoring the levels of phosphorylated myosin light chains. However, little is known about intracellular distribution and strength of cytoskeletal network in ECs when exposed to a spectrum of barrier-active stimuli present in the blood circulation.

Earlier studies have used morphometric and biochemical parameters to describe agonist-induced cytoskeletal remodeling and changes in the EC contractility in response to barrier-disruptive and barrier-protective agonists. Increased permeability induced by thrombin, vascular endothelial growth factor (VEGF), hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>), microtubule disrupter nocodazole, or other agents is associated with robust stress fiber formation and accumulation of phosphorylated regulatory myosin light chains on centrally positioned stress fibers leading to actomyosin contraction, cell retraction, and disruption of EC monolayer integrity.<sup>6–10</sup> In turn, barrier-protective agonists cause enhancement of peripheral F-actin and visible peripheral accumulation of phosphorylated regulatory myosin light chains, suggesting generation of peripheral “tethering” forces.<sup>11,12</sup> Activation of actomyosin contractility in cell cultures has been previously assessed by live microscopy of contracting single cells or cell clusters grown on ultrathin elastic silicone membranes<sup>13,14</sup> or collagen lattices.<sup>15</sup> Alternatively, traction forces generated by single cells were registered by measurements of mechanical interactions between cells and their underlying substrates by using cells seeded on microfabricated arrays of elastomeric, microneedle-like posts.<sup>16</sup> However, these approaches are limited in their applicability to regional analysis of intracellular contractility in the cell monolayers upon treatment with barrier-protective and barrier-disruptive agonists. Atomic force microscopy (AFM) provides a suitable approach for detailed analysis of nanomechanical properties of live cells<sup>17</sup> and organelles,<sup>18</sup> and drug-induced changes in cytoarchitecture and mechanics in cultured cells.<sup>19,20</sup>

In this study we have used AFM to directly examine the current working model of endothelial barrier regulation as a balance between mechanical properties of contractile (centrally positioned) and tethering (distributed on the cell periphery) cytoskeletal network in endothelial permeability responses to bioactive molecules. We used two sets of agonists of different origins, among which thrombin, VEGF, and H<sub>2</sub>O<sub>2</sub> showed barrier-disruptive effects,<sup>6,21–26</sup> and oxidized 1-palmitoyl-2-arachidonoyl-*sn*-glycero-3-phosphocholine (OxPAPC), hepatocyte growth factor (HGF), and iloprost exhibit barrier-protective effects.<sup>6,21,27–32</sup> We measured patterns of agonist-induced changes in local elastic modulus and linked them with immunofluorescence analysis of cytoskeletal remodeling and measurements of EC permeability responses. Finally, barrier-protective effects of OxPAPC, HGF, and iloprost on thrombin-induced EC barrier dysfunction were linked to stiffness redistribution from central to peripheral cellular compartments.

## Methods

### Reagents and cell culture

Primary antibodies to VE-cadherin were purchased from BD Transduction Laboratories (San Diego, California). Texas Red phalloidin and Alexa Fluor 488–conjugated secondary antibodies were purchased from Molecular Probes (Eugene, Oregon). VEGF and HGF were obtained from R&D Systems (Minneapolis, Minnesota); thrombin and iloprost were obtained from Sigma (St. Louis, Missouri). OxPAPC was obtained by exposure of dry lipid to air as described.<sup>27,28,33</sup> The extent of oxidation was measured by positive ion electrospray mass spectrometry described elsewhere.<sup>33</sup> Next, oxidized lipids dissolved in chloroform were stored at –70°C and used within 2 weeks after mass spectrometry testing. All oxidized and nonoxidized phospholipid preparations were analyzed by the *Limulus* amoebocyte assay (BioWhittaker, Frederick, Maryland) and shown negative for endotoxin. Unless specified, all other biochemical reagents were obtained from Sigma. Human pulmonary artery endothelial cells (HPAECs) were obtained from Lonza (Allendale, New Jersey), cultured according to manufacturer’s protocol, and used at passages 5–9.

### Measurement of transendothelial electrical resistance

The cellular barrier properties were analyzed by measurements of transendothelial electrical resistance (TER) across confluent HPAEC monolayers using an electrical cell-substrate impedance sensing system (Applied Biophysics, Troy, New York). TER values from at least six microelectrodes corresponding to each experimental condition were pooled at discrete time points using custom-designed Epool software and plotted versus time as the mean ± SD as described.<sup>28,34</sup>

### Immunofluorescent staining

Endothelial cells grown on glass coverslips were fixed after agonist treatment in 3.7% formaldehyde solution in phosphate-buffered saline (PBS) for 10 minutes at 4°C, washed three times with PBS, permeabilized with PBS containing 0.2% Tween-20 (PBST) and 0.2% Triton X-100 for 30 minutes at room temperature (20°–22°C), and blocked with 2% bovine serum albumin (BSA) in PBST for 30 minutes. Incubation with VE-cadherin antibodies was performed in PBS containing 0.2% Tween-20 and 2% BSA for 1 hour at room temperature followed by staining with Alexa 488–conjugated secondary antibodies (Molecular Probes). Actin filaments were stained with Texas Red–conjugated phalloidin (Molecular Probes) for 1 hour at room temperature. After immunostaining the glass slides were analyzed by using a Nikon video-imaging system (Nikon Instech Co., Tokyo, Japan) consisting of an inverted microscope Nikon Eclipse TE300 with epi-fluorescence module using 60×A/1.40 oil objective connected to a SPOT RT monochrome digital camera and image processor (Diagnostic Instruments, Sterling Heights, Michigan). The




**A Barrier-disruptive agonists:****B Barrier-enhancing agonists:****C Barrier-enhancing + barrier-disruptive agonists:**

Figure 1. Effect of thrombin, VEGF, H<sub>2</sub>O<sub>2</sub>, OxPAPC, HGF, and iloprost on transendothelial electrical resistance. Human pulmonary artery EC monolayers were grown on gold microelectrodes. At the time point indicated by an arrow, cells were treated with (A) 0.2 U/mL thrombin, 200 ng/mL VEGF, 100  $\mu$ M H<sub>2</sub>O<sub>2</sub>; (B) 20  $\mu$ g/mL OxPAPC, 20 ng/mL HGF, 200 ng/mL iloprost; or (C) pretreated with OxPAPC, HGF, or iloprost before thrombin stimulation, and TER was monitored during 3 hours. Results are representative of five independent experiments.




Figure 2. Summary of agonist effects on EC permeability. TER measurements were made at the time points corresponding to maximal TER changes in response to each agonist shown by vertical lines in Figure 1. Shown are pooled data of three to eight independent experiments. Ilo, iloprost; Ox, OxPAPC; Thr, thrombin.

images were recorded and processed using Adobe Photoshop 7.0 (Adobe Systems, San Jose, California) software.

#### *In vitro endothelial permeability assay*

Similar to the measurements of transendothelial albumin clearance,<sup>21</sup> permeability to fluorescein isothiocyanate (FITC)-labeled dextran was assessed across HPAEC monolayers grown on transwell inserts using an In Vitro Vascular Permeability Assay Kit (Millipore, Billerica, Massachusetts) according to manufacturer's protocol, as we have described.<sup>31</sup>

#### *AFM*

Imaging was carried out with a Bioscope atomic force microscope (a prototype of Digital Instruments Bioscope) integrated with a Zeiss Axiovert 135TV inverted light microscope,<sup>35,36</sup> using version 5.12R3 of the NanoScope software. For some experiments a  $150 \times 150 \mu\text{m}^2$  "J" scanner from a Nanoscope III Extended Multimode atomic force microscope from Veeco (Santa Barbara, California) was also used. Imaging of fixed cells in air and PBS buffer was performed in contact mode. Cantilevers with nominal spring constants of  $k = 0.06 \text{ N/m}$  purchased from Veeco were used for imaging and elasticity measurements. A nominal radius of 30 nm was used for the tip radius. The same cantilever was used to compare mechanical properties of all cells. Mechanical properties were measured by acquiring point-by-point force-versus-distance curves over  $32 \times 32$  arrays (force-volume). The tip velocities for these measurements varied between  $1 \mu\text{m/sec}$  and  $3 \mu\text{m/sec}$ . The sensitivity of the photodetector was calibrated by acquiring force-versus-distance curves on a clean glass substrate.

A home-written MatLab (MathWorks, Natick, Massachusetts) code was used to obtain elasticity maps from force-volume data.<sup>37</sup> A line of zero force was defined from the average deflection of points in the force curve corresponding to the positions of the cantilever when it is far away from the surface. The origin of the indentation curve was chosen as the point where the retraction curve intersected the line of zero force. The cell's vertical deformation (penetration depth of the tip) was obtained by subtracting the cantilever deflection from the displacement of the piezo element. These values were plotted along the x-axis of the indentation curve. Indentation forces were calculated by multiplying the elastic constant of the cantilever by the cantilever deflection. To check the consistency of these results, a manual inspection of the force curves was performed and, when necessary, the data were reanalyzed until the computed results and manual examinations agreed reasonably. A value of zero was assigned to the elastic modulus in regions where cells' features were either absent or too thin, and these were consequently excluded from further analysis. The same procedure was followed for data points that exceeded maximum typical values (1 MPa), regardless of the specimen's thickness in the region.

The cell's periphery and nucleus were defined from AFM height images acquired in contact mode. Data points inside a region of the map could be selected for further analysis by choosing the start and end points of polygonal lines. If only two points were selected, the program delivered a cross-section of the selected line. Indentation curves were fitted according to the Hertz model, from which the values of elastic modulus plotted in the maps were obtained. The ratio of elastic moduli at the






Figure 3. Effect of agonists on endothelial monolayer permeability for micromolecules. Human pulmonary artery EC monolayers grown in transwell plates were treated with 20  $\mu$ g/mL OxPAPC, 20 ng/mL HGF, 200 ng/mL iloprost, 0.2 U/mL thrombin (thr), 200 ng/mL VEGF, 100  $\mu$ M H<sub>2</sub>O<sub>2</sub> for 2 hours, or cells pretreated with OxPAPC, HGF, or iloprost (15 minutes) were further challenged with thrombin (2 hours). Measurements of permeability for FITC-labeled dextran were performed as outlined in Methods. Shown are pooled data of three independent experiments. Results are represented as mean  $\pm$  SD. \* $P$  < .01, versus vehicle control; # $P$  < .01, versus stimulation with barrier-disruptive agonists alone.

cell's periphery (Ep) and cell's center (En) was obtained from cross-sections traced along the elasticity map of a cell. Importantly, unknown exact values of the cantilever's spring constant and tip radius are not expected to contribute significantly to the error in the Ep/En ratio.

#### Statistical analysis

Results were expressed as means  $\pm$  SD of three to ten independent experiments. Experimental samples were compared to controls by unpaired Student's *t*-test. For multiple-group comparisons, a one-way variance analysis, followed by the post hoc Fisher's test, were used. A value of  $P$  < .05 was considered statistically significant.

## Results

### Changes in pulmonary endothelial permeability induced by thrombin, VEGF, H<sub>2</sub>O<sub>2</sub>, OxPAPC, HGF, and iloprost

Human pulmonary EC monolayers were treated with thrombin, VEGF, H<sub>2</sub>O<sub>2</sub>, OxPAPC, HGF, and iloprost followed by measurements of TER for 3 hours in parallel experiments. Treatment with thrombin, VEGF, and H<sub>2</sub>O<sub>2</sub> significantly increased EC monolayer permeability<sup>6,24,38,39</sup> that reached maximum at different time points, as monitored






Figure 4. Effect of OxPAPS on thrombin-induced cytoskeletal remodeling and adherens junction integrity. ECs grown on glass coverslips were incubated with iloprost (200 ng/mL, 15 minutes) or thrombin (0.2 U/mL, 15 minutes) alone or with iloprost followed by thrombin (Thr) treatment for 15 minutes. Cells were fixed, and double immunofluorescent staining was performed according to the protocol described in Methods. Cells were probed with Texas red phalloidin to detect actin filaments (A) and with VE-cadherin antibody to label adherens junctions (B). Results are representative of three independent experiments.

Figure 5. Height and deflection images of agonist-stimulated pulmonary EC monolayers. Pulmonary ECs grown on glass coverslips and treated with iloprost (200 ng/mL, 15 minutes), thrombin (0.2 U/mL, 15 minutes), or combination of iloprost and thrombin, as described in previous figures, were used for image acquisition using AFM techniques. (A) AFM height images of larger areas of EC monolayers; (B) deflection images showing more detail of the regions indicated with squares in A. Data were acquired using the same cantilever with 0.06 N/m spring constant in PBS buffer at room temperature, as described in Methods. Shown are representative data of three independent experiments.





by decline in TER (Figure 1, A). EC stimulation with OxPAPC, HGF, and prostacyclin analogue iloprost increased TER, though in different ways (Figure 1, B). Consistent with previous findings,<sup>27,30,32,40</sup> pretreatment with barrier-protective agents OxPAPC, HGF, or iloprost significantly attenuated absolute values of thrombin-induced TER decline. This finding reflects EC barrier compromise and also reduced relative TER changes in response to thrombin in EC pretreated with barrier-protective agonists (Figure 1, C, shown by arrows). TER measurements show that OxPAPC, HGF, and iloprost also attenuated EC barrier dysfunction induced by H<sub>2</sub>O<sub>2</sub> and VEGF (Figure 2).

Agonist-induced permeability changes in human pulmonary EC monolayers were also analyzed by the solute flux assay.<sup>31</sup> EC monolayers grown on semi-permeable membranes were pretreated with barrier-protective or barrier-disruptive agonists alone or with OxPAPC, HGF, or iloprost followed by thrombin challenge, and permeability for FITC-labeled dextran was assessed in transwell assays. Similar to effects on TER, OxPAPC, HGF, and iloprost markedly reduced basal EC monolayer permeability and significantly attenuated thrombin-induced permeability for FITC-labeled dextran (Figure 3).

#### *Agonist-induced remodeling of actin cytoskeleton and adherens junctions*

To link agonist-induced EC permeability with morphological changes, we analyzed redistribution of actin cytoskeleton and adherens junctions by imaging of agonist-stimulated EC monolayers subjected to immunofluorescent staining with Texas Red phalloidin and antibodies to VE-cadherin. Thrombin and iloprost were chosen as representative barrier-disruptive and barrier-protective agonist, respectively. Consistent with previous observations, thrombin caused robust stress fiber formation (Figure 4, A) and disruption of continuous pattern of VE-cadherin peripheral staining (Figure 4, B). In contrast, iloprost induced accumulation of F-actin at the cell periphery (Figure 4, A, shown by arrows) and enhancement of continuous VE-cadherin-positive peripheral staining of ECs in monolayer (Figure 4, B). Significantly, inhibition of thrombin-induced permeability by iloprost (Figures 1, 2) was associated with marked attenuation of thrombin-induced stress fiber formation and partial preservation of peripheral F-actin structure in the iloprost-pretreated ECs (Figure 4, A) that partially preserved the continuity of


adherens junctions (Figure 4, B). We also linked actin cytoskeletal redistribution induced by barrier-protective and barrier-disruptive agents with changes in local elasticity.

#### *Force mapping of agonist-stimulated human pulmonary endothelial cells*

The cell periphery and nucleus in the elasticity map were defined from AFM height images of control and agonist-stimulated cells acquired in contact mode (Figure 5, A). Large-scale AFM deflection images of EC monolayers as well as imaging and elasticity measurements of single cells within EC monolayers provided high-resolution details of cell morphology and allowed analysis of cell shape changes in control and agonist-stimulated ECs. AFM images are consistent with the images obtained using conventional optical microscopy. High-resolution AFM images of EC cytoskeleton in the iloprost-stimulated ECs show increased peripheral cytoskeletal redistribution (Figure 5, B, white arrows). In contrast, thrombin stimulation caused assembly of cytoskeletal fibers in the central part of the cell and created intercellular gaps in thrombin-stimulated ECs (Figure 5B, filled arrows). Pretreatment with iloprost attenuated gap formation caused by thrombin and restored peripheral cytoskeletal structure (Figure 5, B, lower panels). Gap areas decreased in this case to only a few microns. These data are highly consistent with changes in actin cytoskeletal arrangement monitored by immunofluorescent staining of agonist-stimulated EC monolayers (Figure 4).

In agreement with previous work, elasticity maps in our study revealed elastic moduli in the order of 0.1 to 1 MPa (Figure 6, A).<sup>41,42</sup> For the maximum loads used in our measurements (typically ~5 nN), the cell's deformation as a result of the pressure applied by the atomic force microscope tip was about 200 nm. Because this depth corresponds primarily to the cytoskeletal region, and the plasma membrane stiffness is negligible in comparison to the stiffness of the underlying actomyosin cytoskeleton, these measurements depict regional changes in cytoskeletal stiffness induced by barrier-protective and barrier-disruptive agonists. We further depicted the distribution of elastic modulus in control and agonist-stimulated cells as a histogram (Figure 6, A). Although the maximum of the elastic modulus distribution was approximately 0.1 MPa for both vehicle- and iloprost-treated cells, the full width at half-maximum (FWHM) was significantly decreased in the iloprost-treated cells (FWHM

Figure 6. Effects of barrier-disruptive and barrier-protective agonists on intracellular elasticity distribution measured using AFM. (A) Human pulmonary EC monolayers grown on glass coverslips and treated for 15 minutes with vehicle (left panels), 0.2 U/mL thrombin (middle panels), or 200 ng/mL iloprost were fixed in 3.7% formaldehyde and used for elasticity measurements by AFM. Histograms represent the overall distribution of elastic modulus across the entire cell. A Gaussian fit (black dashed line) is superimposed on each histogram. Full widths at half-maximum (FWHM) values of the distributions are 0.2 MPa (vehicle), 0.3 MPa (thrombin), and 0.1 MPa (iloprost). Human pulmonary EC monolayers grown on glass coverslips and treated for 15 minutes with (B) 0.2 U/mL thrombin, 200 ng/mL VEGF, 100  $\mu$ M H<sub>2</sub>O<sub>2</sub>, or (C) 20  $\mu$ g/mL OxPAPC, 20 ng/mL HGF, or 200 ng/mL iloprost were fixed in 3.7% formaldehyde and used for elasticity measurements by AFM. Shown are representative samples of multiple analyzed cells and measurements. Scale in z-axis (elastic modulus): 0–1 MPa for all elasticity maps. Scale is color coded in tones of black, red, yellow, and white, with black corresponding to 0 MPa and white to 1 MPa. Directions of elasticity scans used for calculations of Ep/Ec ratios are shown by arrows.





values of 0.2 MPa for vehicle and 0.1 MPa for iloprost-treated cells, respectively). These results suggest certain decrease in the basal cellular stiffness as result of iloprost treatment. Thrombin challenge increased the maximum of the elastic modulus distribution to about 0.25 MPa. In addition, thrombin-treated cells displayed a wider (FWHM value of 0.3 MPa) distribution of elastic modulus than vehicle cells. The results shown in Figure 6 are highly consistent with thrombin-induced generalized endothelial contraction leading to disruption of EC monolayer integrity, and iloprost-mediated relaxation of central cytoskeletal compartment with still-preserved or even enhanced peripheral stiffness, which is associated with increased EC barrier properties. More detailed analysis of regional stiffness distribution was performed in the next experiments.

The analysis of the overall elastic modulus as a result of agonist action is complicated by several effects, including cell fixation and the AFM technique itself.<sup>36,41,43</sup> On the other hand, experiments with live cells are complicated by relatively low cell-substrate adhesive forces and the rapid action of agonists in time scales difficult to follow with AFM. Therefore, for these preliminary experiments relative variations in the elastic modulus of the peripheral cytoplasm to the elastic modulus in the cell nucleus ( $E_p/E_c$  values) were studied. Differences in the  $E_p/E_c$  ratio were small, but still discernible. The elastic moduli measured in our experiments are directly associated with subcellular mechanical properties.<sup>36</sup> In addition, they provide an indirect connection to intracellular forces through relationships between the elastic modulus, bulk modulus, and Gibbs free energy.<sup>44</sup> Although these relationships have been examined in detail for ionic crystals,<sup>45</sup> they are discussed here only qualitatively. Generally, larger cohesion forces in the cytoskeleton are expected to be reflected by larger values of elastic moduli.

Elasticity maps of agonist-stimulated EC monolayers suggest that barrier-disruptive agonists thrombin,  $H_2O_2$ , and VEGF increased elastic modulus in the central part of the cell ( $E_c$ ) as compared with the cell periphery ( $E_p$ ) (Figure 6, B). Calculated  $E_p/E_c$  ratios were typically less than one (within the range of 0.53–0.65) for characteristic directions along the cells that correlated with the redistribution of actin in fluorescence images. In comparison to barrier-disruptive agents, agonists with barrier-protective properties (OxPAPC, HGF, and iloprost) decreased overall stiffness (mean value across the entire cell, Figure 6) but preserved or even increased the elastic modulus at the cell periphery with respect to the central part of the cell, resulting to the increased  $E_p/E_c$  ratios (Figure 6, C). As a result of inherent differences in the elastic modulus distribution in different cells, selection of the direction for regional stiffness scanning in each cell may cause fluctuations of  $E_p/E_c$  values. However, even with these variations, ECs stimulated with all three barrier-protective agents (OxPAPC, HGF, and iloprost) showed higher  $E_p/E_c$  ratios with respect to control cells and ECs stimulated with barrier-disruptive agonists.

### Barrier-enhancing + barrier-disruptive agonists:




Figure 7. Measurements of intracellular elasticity distribution in agonist-stimulated ECs using AFM. Human pulmonary EC monolayers grown on glass coverslips and pretreated with HGF or iloprost (15 minutes) before thrombin challenge (15 minutes) were fixed in 3.7% formaldehyde and used for elasticity measurements by AFM. Shown are representative samples of multiple measurements. Scale in z-axis (elastic modulus): 0–1 MPa for both elasticity maps. Scale is color coded in tones of black, red, yellow, and white, with black corresponding to 0 MPa and white to 1 MPa.

These results are highly consistent with the model of the maintenance of EC barrier properties via increased tethering forces generated during enhancement of peripheral actomyosin cytoskeleton and cell-cell junctions.<sup>3</sup> Significantly, cell pretreatment with barrier-protective agonists HGF and iloprost, which attenuate thrombin-induced EC barrier dysfunction, reversed the intracellular distribution of elastic modulus and increased  $E_p/E_c$  ratios to 0.95–1.07 (Figure 7).

### Discussion

Here we describe specific patterns of local intracellular elasticity in human pulmonary EC monolayers and link them with actin cytoskeletal remodeling, rearrangement of cell-cell adherens junctions, and barrier response to agonist stimulation. These results support the model of EC barrier regulation as a balance between central contractile and circumferential tethering forces imposed by actomyosin cytoskeleton. In addition, our studies show that protective effects of OxPAPC, HGF, and iloprost against EC hyperpermeability induced by barrier-disruptive agents of different origin are associated with redistribution of intracellular elastic modulus. Protective agonists caused increases in peripheral and decreases in central contractility reflected by changes in the  $E_p/E_c$  ratios.

It is also important to note that marked redistribution of VE-cadherin to the cell junctions caused by iloprost and other barrier-protective agonists and resulting increases in cell-cell adhesiveness may serve as complementary mechanisms enhancing endothelial monolayer barrier properties without affecting cellular elastic modulus.

Earlier studies used biochemical and morphological markers, such as myosin light chain (MLC) phosphorylation, protein translocation from cytosolic to membrane/cytoskeletal fractions, electron microscopy analysis of EC gaps, actin remodeling, morphological enlargement, or disassembly of cell adhesion complexes upon agonist stimulation to characterize endothelial permeability (see Refs. [2,4] for review). These approaches only indirectly implied a role of contractile forces in the regulation of endothelial permeability. Functional assays such as membrane wrinkling assay, collagen lattices, or single-cell traction force analysis were used to confirm activation of EC contraction by edemagenic agonists (thrombin, nocodazole) leading to EC hyperpermeability.<sup>13–16</sup> However, without AFM studies, it was very difficult if not impossible to (1) quantitatively analyze stiffness/elastic modulus in a particular EC contained within the endothelial monolayer; (2) determine the distribution of subcellular mechanical indices; (3) compare effects of barrier-protective and barrier-disruptive agonists on intracellular mechanical properties; and (4) link these data with morphological and functional changes in EC monolayers. An increasing number of studies refers to cortical actin cytoskeletal enhancement as a major mechanism of EC barrier protection. However, mechanical properties of EC peripheral cytoskeleton have not been directly tested. We believe that changes in mechanical properties of cortical cytoskeleton and cell-cell adhesive complexes are keys to understanding the molecular mechanisms of agonist-induced EC barrier enhancement and barrier recovery. These measurements are only possible by using AFM methods including those described in this study. Ongoing studies by our group will further characterize cytoskeletal and cell adhesion protein targets involved in dynamic changes in cortical cytoskeletal mechanics critical for EC barrier protection and recovery.

The barrier-disruptive agonists used in this study trigger various signaling molecules including MLCK, Rho-GTPase, protein kinase C, Erk-1,2, p38 mitogen-activated protein kinases, and NF- $\kappa$ B, which may cause EC barrier compromise.<sup>6,7,46–51</sup> Similarly, agonist-induced barrier-protective effects are also mediated by various signaling pathways including Rac and Cdc42 GTPases, protein kinase A, Epac-Rap1 signaling, and phosphatidylinositol-3-kinase.<sup>29–31,40,52,53</sup> However, the common feature of EC responses to various barrier-disruptive agonists is formation of centrally positioned actomyosin filaments leading to cell retraction, and disruption of cell-cell contacts and EC monolayer integrity. In turn, barrier-protective agonists OxPAPC, HGF, and prostacyclin analogue iloprost tested in this study, though associated with activation of distinct

signaling pathways, however, enhanced peripheral cytoskeleton and peripheral elasticity modulus.

The mechanisms of differential actin cytoskeletal remodeling induced by barrier-protective and barrier-disruptive agents are not yet fully understood. An increasing number of publications including our studies<sup>11,27,54,55</sup> suggest a central role for Rac GTPase in the peripheral actin cytoskeletal remodeling and cell-cell junction assembly. Indeed, Rac activation has been reported in ECs stimulated with OxPAPC, HGF, and prostacyclin.<sup>27,29–31,56</sup> In contrast, activation of Rho GTPase and MLCK, which promote central stress fiber formation, cell retraction, and disruption of cell-cell contacts, has been described in ECs challenged with thrombin, H<sub>2</sub>O<sub>2</sub>, and VEGF.<sup>6,7,9,48</sup>

In summary, this study provides a comprehensive analysis of cytoskeletal remodeling examined in parallel by immunofluorescent staining and AFM methods, and links differential patterns of force distribution in EC monolayers with specific permeability responses. Results of AFM analysis of regional cytoskeletal stiffness in the agonist-stimulated EC monolayers support the model of endothelial barrier regulation via a balance between centrally localized contractile and peripheral tethering forces. The AFM approach described in this study provides a suitable assay to test the role of specific molecules in EC contractility and barrier regulation via force mapping of the individual cells expressing functional mutants of signaling or cytoskeletal proteins within intact EC monolayers. Furthermore, parallel force mapping of macro- and microvascular EC monolayers may help identify the differences in the patterns of cytoskeletal remodeling, tethering forces, and cell-cell adhesive forces observed in the lung macro- and microvascular beds and associated with regional differences in regulation of lung permeability.

## References

- Lum H, Malik AB. Mechanisms of increased endothelial permeability. *Can J Physiol Pharmacol* 1996;74:787–800.
- Dudek SM, Garcia JG. Cytoskeletal regulation of pulmonary vascular permeability. *J Appl Physiol* 2001;91:1487–500.
- Ingber DE. Tensegrity: the architectural basis of cellular mechanotransduction. *Annu Rev Physiol* 1997;59:575–99.
- Mehta D, Malik AB. Signaling mechanisms regulating endothelial permeability. *Physiol Rev* 2006;86:279–367.
- Yuan SY. Protein kinase signaling in the modulation of microvascular permeability. *Vascul Pharmacol* 2002;39:213–23.
- Birukova AA, Smurova K, Birukov KG, Kaibuchi K, Garcia JGN, Verin AD. Role of Rho GTPases in thrombin-induced lung vascular endothelial cells barrier dysfunction. *Microvasc Res* 2004;67:64–77.
- Zhao Y, Davis HW. Hydrogen peroxide-induced cytoskeletal rearrangement in cultured pulmonary endothelial cells. *J Cell Physiol* 1998;174:370–9.
- Pedram A, Razandi M, Levin ER. Deciphering vascular endothelial cell growth factor/vascular permeability factor signaling to vascular permeability. Inhibition by atrial natriuretic peptide. *J Biol Chem* 2002;277:44385–98.
- Sun H, Breslin JW, Zhu J, Yuan SY, Wu MH. Rho and ROCK signaling in VEGF-induced microvascular endothelial hyperpermeability. *Microcirculation* 2006;13:237–47.

10. Birukova AA, Smurova K, Birukov KG, Usatyuk P, Liu F, Kaibuchi K, et al. Microtubule disassembly induces cytoskeletal remodeling and lung vascular barrier dysfunction: role of Rho-dependent mechanisms. *J Cell Physiol* 2004;201:55-70.
11. Garcia JG, Liu F, Verin AD, Birukova A, Dechert MA, Gerthoffer WT, et al. Sphingosine 1-phosphate promotes endothelial cell barrier integrity by Edg-dependent cytoskeletal rearrangement. *J Clin Invest* 2001;108:689-701.
12. Birukov KG, Birukova AA, Dudek SM, Verin AD, Crow MT, Zhan X, et al. Shear stress-mediated cytoskeletal remodeling and cortactin translocation in pulmonary endothelial cells. *Am J Respir Cell Mol Biol* 2002;26:453-64.
13. Bogatcheva NV, Verin AD, Wang P, Birukova AA, Birukov KG, Mirzopoyazova T, et al. Phorbol esters increase MLC phosphorylation and actin remodeling in bovine lung endothelium without increased contraction. *Am J Physiol Lung Cell Mol Physiol* 2003;285:L415-26.
14. Verin AD, Birukova A, Wang P, Liu F, Becker P, Birukov K, et al. Microtubule disassembly increases endothelial cell barrier dysfunction: role of MLC phosphorylation. *Am J Physiol Lung Cell Mol Physiol* 2001;281:L565-74.
15. Byfield FJ, Tikku S, Rothblat GH, Gooch KJ, Levitan I. OxLDL increases endothelial stiffness, force generation, and network formation. *J Lipid Res* 2006;47:715-23.
16. Tan JL, Tien J, Pirone DM, Gray DS, Bhadriraju K, Chen CS. Cells lying on a bed of microneedles: an approach to isolate mechanical force. *Proc Natl Acad Sci U S A* 2003;100:1484-9.
17. Pelling AE, Sehati S, Gralla EB, Valentine JS, Gimzewski JK. Local nanomechanical motion of the cell wall of *Saccharomyces cerevisiae*. *Science* 2004;305:1147-50.
18. Riethmuller C, Schaffer TE, Kienberger F, Stracke W, Oberleithner H. Vacuolar structures can be identified by AFM elasticity mapping. *Ultramicroscopy* 2007;107:895-901.
19. Pesen D, Hoh JH. Micromechanical architecture of the endothelial cell cortex. *Biophys J* 2005;88:670-9.
20. Rotsch C, Radmacher M. Drug-induced changes of cytoskeletal structure and mechanics in fibroblasts: an atomic force microscopy study. *Biophys J* 2000;78:520-35.
21. Garcia JG, Siflinger-Birnboim A, Bizios R, Del Vecchio PJ, Fenton JW, Malik AB. Thrombin-induced increase in albumin permeability across the endothelium. *J Cell Physiol* 1986;128:96-104.
22. Breslin JW, Pappas PJ, Cerveira JJ, Hobson RW, Duran WN. VEGF increases endothelial permeability by separate signaling pathways involving ERK-1/2 and nitric oxide. *Am J Physiol Heart Circ Physiol* 2003;284:H92-H100.
23. Niwa K, Inanami O, Ohta T, Ito S, Karino T, Kuwabara M. p38 MAPK and  $Ca^{2+}$  contribute to hydrogen peroxide-induced increase of permeability in vascular endothelial cells but ERK does not. *Free Radic Res* 2001;35:519-27.
24. Usatyuk PV, Vepa S, Watkins T, He D, Parinandi NL, Natarajan V. Redox regulation of reactive oxygen species-induced p38 MAP kinase activation and barrier dysfunction in lung microvascular endothelial cells. *Antioxid Redox Signal* 2003;5:723-30.
25. Issbrucker K, Marti HH, Hippenstiel S, Springmann G, Voswinckel R, Gaumann A, et al. p38 MAP kinase—a molecular switch between VEGF-induced angiogenesis and vascular hyperpermeability. *FASEB J* 2003;17:262-4.
26. Gavard J, Gutkind JS. VEGF controls endothelial-cell permeability by promoting the beta-arrestin-dependent endocytosis of VE-cadherin. *Nat Cell Biol* 2006;8:1223-34.
27. Birukov KG, Bochkov VN, Birukova AA, Kawkitinarong K, Rios A, Leitner A, et al. Epoxycyclopentenone-containing oxidized phospholipids restore endothelial barrier function via Cdc42 and Rac. *Circ Res* 2004;95:892-901.
28. Birukova AA, Fu P, Chatchavalvanich S, Burdette D, Oskolkova O, Bochkov VN, et al. Polar head groups are important for barrier protective effects of oxidized phospholipids on pulmonary endothelium. *Am J Physiol Lung Cell Mol Physiol* 2007;292:L924-35.
29. Birukova AA, Alekseeva E, Mikaelyan A, Birukov KG. HGF attenuates thrombin-induced permeability in the human pulmonary endothelial cells by Tiam1-mediated activation of the Rac pathway and by Tiam1/Rac-dependent inhibition of the Rho pathway. *FASEB J* 2007;21:2776-86.
30. Liu F, Schaphorst KL, Verin AD, Jacobs K, Birukova A, Day RM, et al. Hepatocyte growth factor enhances endothelial cell barrier function and cortical cytoskeletal rearrangement: potential role of glycogen synthase kinase-3beta. *FASEB J* 2002;16:950-62.
31. Birukova AA, Zagranichnaya T, Alekseeva E, Fu P, Chen W, Jacobson JR, et al. Prostaglandins PGE<sub>2</sub> and PGI<sub>2</sub> promote endothelial barrier enhancement via PKA- and Epac1/Rap1-dependent Rac activation. *Exp Cell Res* 2007;313:2504-20.
32. Farmer PJ, Bernier SG, Lepage A, Guillemette G, Regoli D, Sirois P. Permeability of endothelial monolayers to albumin is increased by bradykinin and inhibited by prostaglandins. *Am J Physiol Lung Cell Mol Physiol* 2001;280:L732-8.
33. Watson AD, Leitinger N, Navab M, Faull KF, Horkko S, Witztum JL, et al. Structural identification by mass spectrometry of oxidized phospholipids in minimally oxidized low density lipoprotein that induce monocyte/endothelial interactions and evidence for their presence in vivo. *J Biol Chem* 1997;272:13597-607.
34. Nonas SA, Miller I, Kawkitinarong K, Chatchavalvanich S, Gorshkova I, Bochkov VN, et al. Oxidized phospholipids reduce vascular leak and inflammation in rat model of acute lung injury. *Am J Respir Crit Care Med* 2006;173:1130-8.
35. Quist AP, Rhee SK, Lin H, Lal R. Physiological role of gap-junctional hemichannels. Extracellular calcium-dependent isosmotic volume regulation. *J Cell Biol* 2000;148:1063-74.
36. Almqvist N, Bhatia R, Primbs G, Desai N, Banerjee S, Lal R. Elasticity and adhesion force mapping reveals real-time clustering of growth factor receptors and associated changes in local cellular rheological properties. *Biophys J* 2004;86:1753-62.
37. Arce FT, Avci R, Beech IB, Cooksey KE, Wigglesworth-Cooksey B. Modification of surface properties of a poly(dimethylsiloxane)-based elastomer, RTV11, upon exposure to seawater. *Langmuir* 2006;22:7217-25.
38. Garcia JG, Davis HW, Patterson CE. Regulation of endothelial cell gap formation and barrier dysfunction: role of myosin light chain phosphorylation. *J Cell Physiol* 1995;163:510-22.
39. Becker PM, Verin AD, Booth MA, Liu F, Birukova A, Garcia JG. Differential regulation of diverse physiological responses to VEGF in pulmonary endothelial cells. *Am J Physiol Lung Cell Mol Physiol* 2001;281:L1500-11.
40. Birukova AA, Malyukova I, Mikaelyan A, Fu P, Birukov KG. Tiam1 and betaPIX mediate Rac-dependent endothelial barrier protective response to oxidized phospholipids. *J Cell Physiol* 2007;211:608-17.
41. Arce FT, Whitlock JL, Birukova AA, Birukov KG, Arnsdorf MF, Lal R, et al. Regulation of the micromechanical properties of pulmonary endothelium by SIP and thrombin: role of cortactin. *Biophys J* 2008;95:886-94.
42. Hutter JL, Chen J, Wan WK, Uniyal S, Leabu M, Chan BM. Atomic force microscopy investigation of the dependence of cellular elastic moduli on glutaraldehyde fixation. *J Microsc* 2005;219:61-8.
43. Moloney M, McDonnell L, O'Shea H. Atomic force microscopy of BHK-21 cells: an investigation of cell fixation techniques. *Ultramicroscopy* 2004;100:153-61.
44. Landau LD, Lifschitz EM. Theory of elasticity. Oxford: Pergamon Press; 1986.
45. Fraxedas J, Garcia-Manyes S, Gorostiza P, Sanz F. Nanoindentation: toward the sensing of atomic interactions. *Proc Natl Acad Sci U S A* 2002;99:5228-32.
46. Huot J, Houle F, Rousseau S, Deschesnes RG, Shah GM, Landry J. SAPK2/p38-dependent F-actin reorganization regulates early membrane blebbing during stress-induced apoptosis. *J Cell Biol* 1998;143:1361-73.



47. Rousseau S, Houle F, Landry J, Huot J. p38 MAP kinase activation by vascular endothelial growth factor mediates actin reorganization and cell migration in human endothelial cells. *Oncogene* 1997;15:2169-77.
48. van Nieuw Amerongen GP, Koolwijk P, Versteilen A, van Hinsbergh VW. Involvement of RhoA/Rho kinase signaling in VEGF-induced endothelial cell migration and angiogenesis in vitro. *Arterioscler Thromb Vasc Biol* 2003;23:211-7.
49. Kevil CG, Oshima T, Alexander JS. The role of p38 MAP kinase in hydrogen peroxide mediated endothelial solute permeability. *Endothelium* 2001;8:107-16.
50. Bowie A, O'Neill LA. Oxidative stress and nuclear factor-kappaB activation: a reassessment of the evidence in the light of recent discoveries. *Biochem Pharmacol* 2000;59:13-23.
51. Tolando R, Jovanovic A, Brigelius-Flohe R, Ursini F, Maiorino M. Reactive oxygen species and proinflammatory cytokine signaling in endothelial cells: effect of selenium supplementation. *Free Radic Biol Med* 2000;28:979-86.
52. Birukova AA, Chatchavalvanich S, Oskolkova O, Bochkov VN, Birukov KG. Signaling pathways involved in OxPAPC-induced pulmonary endothelial barrier protection. *Microvasc Res* 2007;73:173-81.
53. Singleton PA, Dudek SM, Chiang ET, Garcia JG. Regulation of sphingosine 1-phosphate-induced endothelial cytoskeletal rearrangement and barrier enhancement by S1P1 receptor, PI3 kinase, Tiam1/Rac1, and alpha-actinin. *FASEB J* 2005;19:1646-56.
54. Dudek SM, Jacobson JR, Chiang ET, Birukov KG, Wang P, Zhan X, et al. Pulmonary endothelial cell barrier enhancement by sphingosine 1-phosphate: roles for cortactin and myosin light chain kinase. *J Biol Chem* 2004;279:24692-700.
55. Birukova AA, Malyukova I, Poroyko V, Birukov KG. Paxillin- $\beta$ -catenin interactions are involved in Rac/Cdc42-mediated endothelial barrier-protective response to oxidized phospholipids. *Am J Physiol Lung Cell Mol Physiol* 2007;293:L199-211.
56. Fukuhara S, Sakurai A, Sano H, Yamagishi A, Somekawa S, Takakura N, et al. Cyclic AMP potentiates vascular endothelial cadherin-mediated cell-cell contact to enhance endothelial barrier function through an Epac-Rap1 signaling pathway. *Mol Cell Biol* 2005;25:136-46.